Metraipolis › archive › dc_bccd1303eecc

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia… — Europe PMC PMID:41526617

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41526617
DOI
10.1038/s41375-[numero omesso]-1
License (as archived)
solo-consultazione
Archived
2026-11-06T21:34:30.838Z
SHA-256 of the archived text
2de480d245e3e0277106a54376d40fee6b6434e13954580d5ef19a931f095011
Stable URL of this page
https://metraipolis.com/documento/dc_bccd1303eecc

How to cite

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia… — Europe PMC PMID:41526617 — Europe PMC (en), https://europepmc.org/article/MED/41526617 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bccd1303eecc (Metraipolis archive dc_bccd1303eecc, sha256 2de480d245e3e0277106a54376d40fee6b6434e13954580d5ef19a931f095011)
BibTeX
@misc{dcbccd1303eecc,
  title = {Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia… — Europe PMC PMID:41526617},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41526617},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bccd1303eecc; sha256 2de480d245e3e0277106a54376d40fee6b6434e13954580d5ef19a931f095011},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41526617. Agents can read the archived copy with the MCP tool read_document.